NYSEAMERICAN:PHGE BiomX (PHGE) Stock Price, News & Analysis $0.52 -0.05 (-8.61%) As of 10:22 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesSEC FilingsShort InterestBuy This Stock About BiomX Stock (NYSEAMERICAN:PHGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BiomX alerts:Sign Up Key Stats Today's Range$0.49▼$0.5850-Day Range N/A52-Week Range$0.48▼$4.99Volume598,464 shsAverage Volume85,139 shsMarket Capitalization$9.45 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingBuy Company OverviewBiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Read More… Remove Ads BiomX Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScorePHGE MarketRank™: BiomX scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiomX has only been the subject of 1 research reports in the past 90 days.Read more about BiomX's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for BiomX are expected to decrease in the coming year, from ($2.77) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiomX is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiomX is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomX has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BiomX's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.25% of the float of BiomX has been sold short.Short Interest Ratio / Days to CoverBiomX has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BiomX has recently increased by 24.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomX does not currently pay a dividend.Dividend GrowthBiomX does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.25% of the float of BiomX has been sold short.Short Interest Ratio / Days to CoverBiomX has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BiomX has recently increased by 24.41%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment-1.00 News SentimentBiomX has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BiomX this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BiomX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.01% of the stock of BiomX is held by insiders.Percentage Held by Institutions40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BiomX's insider trading history. Receive PHGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter. Email Address PHGE Stock News HeadlinesBiomX (PHGE) Expected to Announce Quarterly Earnings on WednesdayMarch 31 at 2:12 AM | americanbankingnews.comBiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 MillionFebruary 26, 2025 | finance.yahoo.comThe unusual signal flashing green againSomething fascinating happened in April... While a lot of Wall Street institutions were opening new positions in a falling stock, something different showed up on my screen. A special set of candles had just turned green - signaling the kind of momentum surge I'd seen only a handful of times before. What happened next? The stock soared 45% on the underlying stock in just a few weeks and 227% for anyone who traded the options. Naturally, there would have been smaller wins and those that would not have worked out, but this wasn't some penny stock or crypto play… It was ARM Holdings - a major semiconductor player that had just shed 9% of its value.March 31, 2025 | ProsperityPub (Ad)BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing StandardsDecember 16, 2024 | markets.businessinsider.comBiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net Income Amid Rising ExpensesNovember 16, 2024 | finance.yahoo.comBiomX Inc: Promising Clinical Advancements and Strong Financial Position Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comBiomX Inc. Reports Q3 2024 Financial TurnaroundNovember 15, 2024 | markets.businessinsider.comBiomX announces mandatory unit separationOctober 16, 2024 | finance.yahoo.comSee More Headlines PHGE Stock Analysis - Frequently Asked Questions How have PHGE shares performed this year? BiomX's stock was trading at $0.5870 at the start of the year. Since then, PHGE shares have decreased by 11.4% and is now trading at $0.52. View the best growth stocks for 2025 here. How were BiomX's earnings last quarter? BiomX Inc. (NYSEAMERICAN:PHGE) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.03. How do I buy shares of BiomX? Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BiomX own? Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Moderna (MRNA), T2 Biosystems (TTOO), Chegg (CHGG), Aldeyra Therapeutics (ALDX), Nokia Oyj (NOK), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings11/14/2023Today3/31/2025Next Earnings (Estimated)5/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:PHGE CIK1739174 Webwww.biomx.com Phone972-7-2394-2377FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+284.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,539.72% Return on Assets-84.14% Debt Debt-to-Equity RatioN/A Current Ratio3.17 Quick Ratio3.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book0.78Miscellaneous Outstanding Shares18,180,000Free Float17,630,000Market Cap$9.45 million OptionableN/A Beta1.27 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NYSEAMERICAN:PHGE) was last updated on 3/31/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiomX Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BiomX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.